Targeting Tumor Angiogenesis in Gastrointestinal Malignancies

Author(s): Paul R. Kunk, Erika Ramsdale, Osama E. Rahma

Journal Name: Current Angiogenesis (Discontinued)

Volume 4 , Issue 1 , 2015

Graphical Abstract:


Gastrointestinal [GI] malignancies are common and frequently lethal neoplasms. As our understanding of GI cancers deepens, more pathways are discovered that play key roles in tumorigenesis and metastasis. Angiogenesis has emerged as a critical pathway in many cancers, particularly in GI cancers. The discovery of a complex network of signals, including vascular epithelial growth factor [VEGF], led to the emergence of a new class of cancer therapies targeting angiogenesis. Bevacizumab was the first to emerge, gaining US Food and Drug Administration [FDA] approval in 2004 for the treatment of advanced colorectal cancer; since then, several antiangiogenic agents have become clinically available, and numerous others are in clinical or preclinical testing. This review will focus on anti-angiogenesis therapies in GI malignancies.

Keywords: Anti-angiogenesis, bevacizumab, GI cancer, tumor angiogenesis, Tyrosine kinase inhibitor, VEGF.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [37 - 45]
Pages: 9
DOI: 10.2174/221155280401160517170303

Article Metrics

PDF: 13